Nevertheless, resistance to TMZ and/or disease progression invariably occur in GBM independently of O6-methylguanine-DNA methyltransferase (MGMT) presence (2) leading to a poor clinical outcome and a median overall-survival of 14.6 months. This evidence concerns the gene MGMT and glioblastoma.